AG-120

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Acute Myeloid LeukemiaMyelodysplastic SyndromesAcute Myeloid Leukemia (AML)Refractory Acute Myeloid LeukemiaAdvanced Hematologic MalignanciesChondrosarcoma

235 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

1

Idamycin

Pfizer

Phase 3

602

Novantrone

Pfizer

Phase 3

343

Xospata

Astellas

Phase 3

244

Fludara

Sanofi

Phase 3

185

Vepesid

AAvyxa

Phase 3

526

Cerubidine

HHikma Pharmaceuticals LLC

Phase 3

427

Mylotarg

WWyeth-Lederle Vaccines

Phase 3

388

Vanflyta

Daiichi Sankyo

Phase 3

169

Neupogen

EEastern Cooperative Oncology Group

Phase 3

3010

Nexavar

Bayer

Phase 3

12Show 43 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia3 trials

A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

Active, not recruiting·Bristol-Myers Squibb·Phase 1/2·NCT02677922·130 enrolled

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

Active, not recruiting·Institut de Recherches Internationales Servier·Phase 1·NCT02632708·153 enrolled

A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy.

Active, not recruiting·SStichting Hemato-Oncologie voor Volwassenen Nederland·Phase 3·NCT03839771·968 enrolled

Low Grade Glioma1 trial

Study of AG-120 and AG-881 in Subjects With Low Grade Glioma

Completed·Institut de Recherches Internationales Servier·Phase 1·NCT03343197·49 enrolled

Cholangiocarcinoma1 trial

Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)

Completed·Institut de Recherches Internationales Servier·Phase 3·NCT02989857·187 enrolled

Glioma1 trial

Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation

Completed·Institut de Recherches Internationales Servier·Phase 1·NCT02073994·174 enrolled

Relapsed/Refractory AML1 trial

A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

Withdrawn·YYale University·Phase 2·NCT04044209

6 more indications

Advanced Hematologic Malignancies1 trial

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Recruiting·Institut de Recherches Internationales Servier·Phase 1·NCT02074839·291 enrolled

Moderate Hepatic Impairment1 trial

A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function

Completed·AAgios Pharmaceuticals, Inc.·Phase 1·NCT03282513·33 enrolled

Chondrosarcoma1 trial

AG-120 in People With IDH1 Mutant Chondrosarcoma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04278781·6 enrolled

Refractory Acute Myeloid Leukemia1 trial

A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)

Recruiting·BBeat AML, LLC·Preclinical·NCT03013998·3,000 enrolled

Myelodysplastic Syndromes1 trial

A Single-arm Phase II Multicenter Study of IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome

Active, not recruiting·GGroupe Francophone des Myelodysplasies·Phase 2·NCT03503409·68 enrolled

Acute Myeloid Leukemia (AML)1 trial

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination With Azacitidine in Subjects ≥ 18 Years of Age With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation

Active, not recruiting·Institut de Recherches Internationales Servier·Phase 3·NCT03173248·146 enrolled

Details

Drug Info

Related News